Platelet-rich Plasma (PRP)

Platelet-rich plasma, commonly abbreviated as PRP, represents one of the most widely utilized regenerative medicine therapies in equine practice for supporting tissue healing and addressing joint disease. This autologous biologic treatment is prepared from the patient's own blood through a process that concentrates platelets to several times their normal blood levels. Platelets contain abundant growth factors and bioactive proteins that play essential roles in tissue repair and regeneration, making concentrated platelet preparations valuable tools for supporting healing in injuries that might otherwise heal slowly or incompletely.

The mechanism of action of PRP centers on the release of growth factors stored within platelet granules when platelets are activated at the treatment site. Key growth factors delivered by PRP include platelet-derived growth factor (PDGF), transforming growth factor beta (TGF-β), vascular endothelial growth factor (VEGF), insulin-like growth factor (IGF-1), and epidermal growth factor (EGF). These signaling molecules stimulate cellular proliferation, attract stem cells and other reparative cells to the injury site, promote new blood vessel formation, and modulate inflammation. The combined effects support more robust and potentially higher quality tissue healing than might occur naturally.

PRP is prepared through a relatively straightforward process that can be performed in the field or clinic setting using commercially available preparation kits. Blood is collected from the patient's jugular vein into specialized collection tubes, then processed through centrifugation to separate blood components. The platelet-rich layer is then extracted for injection. Various commercial systems and protocols exist, producing PRP preparations with different characteristics including platelet concentration, presence or absence of white blood cells, and activation status. These variations may influence therapeutic effects for different applications.

The safety profile of PRP is excellent owing to its autologous nature, eliminating concerns about immune rejection, allergic reactions, or disease transmission that might accompany products derived from other sources. The primary risks associated with PRP therapy relate to the injection procedure itself, including the possibility of introducing infection into treatment sites, making sterile technique essential. Because PRP stimulates biological healing processes rather than suppressing inflammation like corticosteroids, it does not carry risks of cartilage damage, metabolic effects, or laminitis that concern some practitioners regarding other joint therapies. Veterinary guidance is essential for proper patient selection, preparation, and administration to optimize outcomes.

Soft tissue injuries, particularly tendon and ligament lesions, represent the most well-established and extensively studied application of PRP therapy in equine medicine. Tendon injuries including superficial digital flexor tendon lesions and deep digital flexor tendon damage are common career-ending injuries in performance horses that have historically carried poor prognoses for return to previous performance levels. PRP injection directly into tendon lesions provides concentrated growth factors that support more complete healing with potentially better tissue quality than natural healing alone. Research has demonstrated improved ultrasonographic healing patterns and reduced re-injury rates in PRP-treated tendons compared to conventional management.

Suspensory ligament injuries represent another common soft tissue application for PRP therapy. Both proximal suspensory desmitis and branch injuries can benefit from PRP's regenerative effects. The growth factors delivered by PRP support fibroblast activity and collagen production essential for ligament repair. Other ligamentous injuries including collateral ligament damage and check ligament lesions may similarly be treated with PRP as part of comprehensive injury management. The goal in all soft tissue applications is supporting more complete healing that produces tissue capable of withstanding the mechanical demands placed on it during athletic function.

Intra-articular PRP injection for joint disease has become increasingly common as understanding of PRP's effects on joint tissues has grown. While PRP does not have the same immediate anti-inflammatory potency as corticosteroids, it may provide beneficial effects on cartilage and synovial membrane health through growth factor-mediated mechanisms. PRP contains anti-inflammatory cytokines that can help modulate joint inflammation while simultaneously supporting tissue health. Applications include osteoarthritis management, synovitis treatment, and post-surgical joint therapy. Some practitioners combine PRP with other intra-articular treatments to address multiple aspects of joint pathology.

Wound healing represents an additional application of PRP therapy, particularly for wounds that are healing slowly or incompletely. The growth factors in PRP can stimulate wound bed granulation, epithelialization, and tissue remodeling. Chronic wounds, surgical incisions at risk for dehiscence, and wounds in challenging locations may benefit from PRP application. The treatment can be delivered through injection around wound margins or topical application of activated PRP gel depending on wound characteristics.

Patient selection for PRP therapy considers factors including the nature and severity of injury, timing since injury occurrence, previous treatments attempted, and treatment goals. PRP is often most effective when used relatively early in the injury course while active healing processes can be augmented. Chronic, stable lesions may show less response than acute injuries. Concurrent management including appropriate rehabilitation protocols enhances PRP treatment outcomes, as the biological support provided by PRP must be accompanied by appropriate mechanical loading patterns during healing.

PRP dosing and administration protocols vary based on the treatment site, specific preparation system used, and veterinarian preference, with no universally standardized protocol across all applications. The concentration of platelets achieved during preparation influences therapeutic potential, with most commercial systems targeting platelet concentrations three to five times baseline blood levels. Higher concentrations are not necessarily better, as excessive platelet concentrations may actually impair healing in some applications. The volume of PRP prepared from a single blood collection typically ranges from 3-15 milliliters depending on the preparation system and initial blood volume collected.

For tendon and ligament lesions, PRP is typically injected directly into the lesion under ultrasound guidance to ensure accurate placement within the damaged tissue. Injection volumes depend on lesion size, with larger core lesions potentially receiving larger volumes distributed throughout the affected area. Multiple injection sites within a single lesion help ensure adequate coverage. The treatment may be performed as a single injection or as a series of treatments at intervals of two to four weeks depending on the lesion response and veterinarian protocol. Concurrent use of intralesional stem cells with PRP represents a combination approach some practitioners employ for severe injuries.

Intra-articular PRP administration for joint disease follows standard joint injection techniques with appropriate sterile preparation and typically sedation for patient cooperation. Injection volumes generally range from 4-10 milliliters depending on joint size. Single injection protocols are common for joint applications, though repeat injections at monthly intervals may be performed for chronic conditions. The optimal number and timing of PRP joint injections continues to be investigated, with protocols varying among practitioners. Some combine PRP with hyaluronic acid in the same injection to provide both growth factor stimulation and viscosupplementation.

The blood collection and processing phase precedes administration and requires appropriate planning and equipment. Most PRP systems require collection of 20-60 milliliters of blood from the jugular vein using specialized collection tubes containing anticoagulant. Centrifugation follows according to the specific system's protocol, which may involve single or double spin techniques with defined parameters for time and speed. The platelet-rich fraction is then carefully extracted, avoiding contamination with red blood cells in systems designed to exclude them. Some systems include an activation step before injection while others rely on in-situ activation upon contact with tissues.

Post-treatment management varies substantially between soft tissue and joint applications. Following intralesional PRP injection for tendon or ligament injuries, controlled exercise rehabilitation programs are essential for optimal outcomes. These programs typically begin with stall rest or small paddock turnout, progressing through hand walking, controlled exercise, and eventually return to full work over periods of months. The specific timeline depends on injury severity and healing response monitored through serial ultrasound examinations. Post-joint-injection care is generally less restrictive, with return to exercise following brief rest periods similar to other joint therapies.

Follow-up evaluation after PRP treatment assesses healing response and guides ongoing management decisions. For soft tissue injuries, serial ultrasound examinations at four to eight week intervals monitor tissue healing and help determine appropriate progression through rehabilitation. Response to intra-articular PRP is evaluated through clinical improvement in lameness and joint effusion. Additional treatments may be recommended based on response assessment.

Platelet-rich plasma therapy demonstrates an excellent safety profile reflecting its autologous nature and the body's familiarity with its own biological components. The most commonly observed effect following PRP injection is transient swelling or effusion at the treatment site, occurring to some degree in many treated horses. For joint injections, this manifests as temporary increased joint effusion. For intralesional tendon injections, localized swelling around the injection site may be noted. This reaction typically represents the normal biological response to concentrated growth factor delivery and the injection procedure itself, generally resolving within 24-72 hours without specific intervention.

Transient lameness or discomfort following PRP injection may occur, particularly following intralesional injection into already-injured tendons or ligaments. This temporary increase in sensitivity reflects the inflammatory component of the healing cascade that PRP initiates. The discomfort is usually mild to moderate and self-limiting, resolving over several days as initial inflammatory responses subside and healing processes progress. Ice application, hand walking, and appropriate short-term analgesic use may help manage post-injection discomfort. Severe or worsening lameness warrants veterinary evaluation to rule out complications.

Serious adverse effects from PRP therapy are rare when proper preparation and administration techniques are employed. Because PRP contains only the patient's own biological material, there is no risk of allergic reactions, immune rejection, or disease transmission that might accompany foreign biological products. The growth factors in PRP are identical to those the body naturally produces, eliminating concerns about foreign substance reactions. Unlike corticosteroid therapies, PRP does not carry risks of cartilage damage, metabolic effects, or laminitis, representing a significant safety advantage for appropriate applications.

Infection represents the primary serious risk associated with any injection therapy, including PRP administration. Introducing bacteria into joint spaces or tissue planes during the injection procedure can result in serious infections requiring aggressive treatment. Proper sterile technique throughout blood collection, processing, and injection minimizes this risk. Signs of developing infection including progressive swelling, heat, pain, fever, and discharge warrant immediate veterinary attention. The blood collection phase carries minimal risk of complications, with occasional minor bruising at the jugular venipuncture site.

Unlike conventional pharmaceutical therapies, PRP does not have defined adverse drug reactions or toxicity profiles since it contains no synthetic medications. Variations in treatment response relate more to factors affecting healing biology than to adverse medication effects. Some horses show minimal response to PRP therapy, which represents lack of efficacy rather than an adverse effect and may indicate need for alternative approaches or combination therapies.

Active infection at or near the intended treatment site represents the primary contraindication for PRP therapy. Introducing concentrated growth factors into an infected environment risks accelerating bacterial proliferation and potentially worsening the infection. Joint infections, septic tenosynovitis, or infected wounds should be controlled before considering PRP treatment. Horses with suspected infections should have appropriate diagnostic evaluation including culture and cytology to confirm infection status before treatment decisions. Systemic infections affecting overall health status may similarly contraindicate elective regenerative therapies until the infection is addressed.

Certain platelet disorders or blood conditions may affect PRP therapy suitability or expected outcomes. Horses with significantly reduced platelet counts (thrombocytopenia) would produce less concentrated PRP potentially limiting therapeutic benefit. Conditions affecting platelet function could similarly impact treatment efficacy. Horses with coagulation disorders may face elevated bleeding risks from blood collection and injection procedures. Anemia severe enough to limit blood collection volumes could preclude preparation of adequate PRP quantities. Evaluation of blood status may be warranted for horses with known hematologic abnormalities or those showing unexplained signs that might indicate blood disorders.

Malignant tumors or cancer near proposed treatment sites raise theoretical concerns about PRP use. The growth factors in PRP that support tissue healing could theoretically promote growth of cancerous cells if present. While this concern is primarily theoretical and not well-documented clinically, most practitioners avoid PRP treatment in areas with known or suspected malignancy. Horses with systemic cancer may not be appropriate candidates for elective regenerative procedures depending on overall health status and prognosis.

Chronic, stable injuries that have completed their healing response may show limited benefit from PRP therapy. The growth factors in PRP primarily support active healing processes, and injuries that have reached a chronic, stable state with mature scar tissue may not respond as well as acute or subacute injuries where healing is ongoing. While PRP can still be considered for chronic conditions, setting appropriate expectations regarding likely outcomes becomes important. Severely degenerated joints or extensive tissue loss beyond repair capacity may similarly show limited response to regenerative approaches.

Platelet-rich plasma therapy, as an autologous biologic treatment, has minimal drug interaction concerns compared to conventional pharmaceuticals. The growth factors and proteins in PRP function through natural biological pathways that are not significantly altered by most concurrent medications. This compatibility allows PRP to be incorporated into multimodal treatment protocols involving various other therapies without concern for adverse drug interactions. However, certain medications may theoretically affect either PRP production or the biological responses to treatment.

Non-steroidal anti-inflammatory drugs have received attention regarding potential interactions with PRP therapy. Theoretical concerns suggest that NSAIDs might inhibit the inflammatory component of healing that PRP initiates, potentially reducing treatment efficacy. Some practitioners recommend discontinuing NSAIDs before PRP treatment and avoiding them during the early post-treatment period to allow full expression of PRP effects. However, clinical evidence clearly demonstrating significant interference is limited, and the practical management of painful injuries often necessitates some analgesic use. Discuss NSAID use with your veterinarian when planning PRP treatment.

Corticosteroid interactions with PRP therapy warrant consideration. The anti-inflammatory and potentially immunosuppressive effects of corticosteroids could theoretically modulate the cellular responses to PRP growth factors. Most practitioners avoid simultaneous intra-articular administration of corticosteroids and PRP to the same site. When transitioning between corticosteroid and PRP therapy for joint management, allowing adequate interval between treatments enables assessment of each therapy's individual effects. Systemic corticosteroids might similarly affect healing responses, though the clinical significance is not well-established.

Other regenerative and biologic therapies may be combined with PRP as part of comprehensive treatment approaches. IRAP (Interleukin-1 Receptor Antagonist Protein) addresses inflammatory pathways through different mechanisms than PRP's growth factor stimulation, making combination approaches reasonable for joint conditions. Stem cell therapies are frequently combined with PRP, with the growth factors in PRP thought to potentially enhance stem cell survival and activity. Hyaluronic acid can be administered alongside PRP for joints requiring both growth factor support and viscosupplementation.

Competition horses receiving PRP therapy face minimal regulatory concerns since the treatment involves only the horse's own biological material without added drugs. PRP is not classified as a prohibited substance by FEI, USEF, or racing jurisdictions because it contains no exogenous medications. However, any concurrent pharmaceutical treatments used alongside PRP may have their own competition implications. Documentation of all treatments remains important for competition horses subject to regulatory oversight.

Proper patient monitoring throughout PRP treatment and recovery periods supports optimal outcomes. For soft tissue injuries, serial ultrasonographic evaluation provides objective assessment of tissue healing response, typically performed at four to eight week intervals following treatment. Clinical lameness evaluation supplements imaging findings in assessing overall progress. Joint applications are monitored through lameness evaluation and assessment of joint effusion and range of motion. If improvement is inadequate despite appropriate post-treatment management, additional PRP treatments, alternative therapies, or further diagnostic investigation may be warranted.

Special population considerations for PRP therapy are minimal compared to pharmaceutical alternatives. Geriatric horses may show somewhat reduced healing responses due to age-related changes in regenerative capacity, though PRP can still provide benefit. Young horses with immature musculoskeletal systems may respond particularly well to regenerative support during injury healing. Pregnant mares are not specifically contraindicated from PRP therapy when treatment is needed, though the advisability of any procedures during pregnancy requires appropriate consideration. Breeding horses of either sex do not face specific contraindications for PRP use.

Competition and performance horses represent a significant population receiving PRP therapy, and scheduling considerations apply. While PRP itself is not a regulated substance, the post-treatment rest and rehabilitation required for soft tissue injuries may significantly impact training and competition schedules. For joint applications, transient post-injection effects should be allowed to resolve before competition, though the duration is generally brief. Treatment records should be maintained for horses subject to regulatory oversight, documenting the autologous nature of PRP therapy. Current regulatory rules should be verified before treating competition horses.

Administration precautions center on sterile technique and proper blood handling throughout the PRP preparation and injection process. Blood collection should follow standard venipuncture protocols with appropriate site preparation. Processing should occur in clean environments following manufacturer protocols for the specific preparation system used. The PRP product should be protected from contamination during transfer to injection syringes. Injection site preparation follows standard sterile protocols for the specific treatment location. Proper handling maintains both product sterility and optimal platelet viability.

Post-treatment rehabilitation is critical for optimizing PRP outcomes in soft tissue injuries and represents a key aspect of treatment planning. PRP provides biological support for healing, but appropriate mechanical loading through controlled exercise is essential for developing properly organized, functional repair tissue. Premature return to full work risks re-injury of incompletely healed tissue, while excessive restriction may allow formation of disorganized scar tissue. Your veterinarian will provide specific rehabilitation guidelines based on the injury type, location, severity, and healing progress observed on follow-up examinations.

Platelet-rich plasma preparation typically occurs immediately before administration, as the fresh product provides optimal platelet viability and growth factor content. Most clinical applications involve same-day processing from blood collection through injection, eliminating need for extended storage. The centrifugation and separation steps should be completed efficiently following blood collection to maintain platelet function. Once prepared, PRP should be used promptly, ideally within one to two hours, to ensure platelets remain viable and bioactive proteins are delivered in optimal condition.

When circumstances prevent immediate administration, short-term storage of prepared PRP can maintain adequate quality for several hours. Room temperature storage is generally appropriate for brief periods, as refrigeration may actually impair platelet function. If delay between preparation and injection is anticipated, the PRP container should be gently agitated periodically to prevent cell settling. Extended storage is generally not recommended for fresh PRP, as platelet viability and growth factor activity decline progressively with time.

Some specialized protocols involve freezing PRP for later use, typically after activation to release growth factors into the plasma. Freeze-thaw cycles damage intact platelets, but the released growth factors can remain active in frozen plasma preparations. This approach allows stockpiling of multiple treatment doses from single blood collections, similar to IRAP protocols. However, frozen preparations lack the cellular component of fresh PRP and may have different therapeutic characteristics. Your veterinarian can advise whether frozen PRP protocols are appropriate for specific applications.

Handling of blood products and PRP requires standard biosafety practices. Gloves should be worn when handling blood and plasma preparations. Equipment should be properly disposed of following blood product protocols applicable to the practice setting. While equine blood products pose minimal human health risk, standard precautions represent good practice. Collection tubes, processing equipment, and injection supplies should all be handled according to manufacturer specifications and disposed of appropriately. Cross-contamination between patients must be avoided through proper equipment handling and labeling.

Draft horses receiving PRP therapy benefit from the treatment's excellent safety profile and absence of metabolic risks that complicate corticosteroid use in these metabolically sensitive breeds. The larger blood volumes in draft horses readily accommodate the collection amounts needed for PRP preparation. Soft tissue injuries in draft breeds including tendon and ligament damage can be treated with PRP following the same principles applied to lighter breeds. Joint applications similarly do not require dose modification based on breed, though larger joint volumes should be considered when planning treatment volumes. The absence of laminitis risk makes PRP particularly attractive for draft breeds where corticosteroid alternatives pose elevated concerns.

Light horses and warmbloods represent the populations most frequently receiving PRP therapy, particularly for sport-related soft tissue injuries. Tendon injuries in racehorses and sport horses have been extensively treated with PRP, with this population contributing significantly to clinical outcome data. Standard PRP protocols apply well to average-sized light horses. The high value of many performance horses combined with the career-threatening nature of tendon and ligament injuries drives interest in regenerative approaches offering improved healing outcomes. Competition regulations permitting PRP use without restriction facilitate treatment planning for sport horses.

Ponies and miniature horses can receive PRP therapy with appropriate adjustments for their smaller size. Blood collection volumes should be scaled to body size to avoid excessive blood loss, which may limit the amount of PRP that can be prepared from single collections. For very small equids, this may mean smaller treatment volumes or consideration of whether adequate PRP can be obtained. The absence of metabolic risks makes PRP particularly appropriate for ponies and miniatures, which commonly face metabolic concerns that limit corticosteroid options. Soft tissue injuries in ponies driven for competition or pleasure benefit from the same regenerative support PRP provides to larger horses.

Breed-specific genetic conditions do not directly affect PRP therapy response or safety, though they may influence the underlying conditions being treated. Quarter Horses with PSSM may benefit from regenerative support for the myotendinous junction injuries sometimes associated with this condition. Horses with HYPP can receive PRP treatment with appropriate management of stress around the procedure. No breed-specific sensitivities to PRP have been identified, consistent with the autologous nature of the therapy. Individual patient factors including the specific injury, chronicity, concurrent conditions, and treatment goals guide therapy decisions more than breed considerations.

Within the regenerative medicine category, several autologous biological therapies offer alternative or complementary approaches to PRP. IRAP (Interleukin-1 Receptor Antagonist Protein) focuses on anti-inflammatory protein delivery rather than growth factor stimulation, making it particularly valuable for joint inflammation and osteoarthritis where blocking inflammatory pathways is a primary goal. Pro-Stride is a newer autologous protein solution that combines concentrated platelets with anti-inflammatory proteins in a single same-day preparation, providing elements of both PRP and IRAP therapies. Stem cell therapies using mesenchymal stem cells derived from bone marrow or adipose tissue offer another regenerative approach, with PRP sometimes used as an adjunct to enhance stem cell survival and activity.

Corticosteroids represent the traditional pharmaceutical approach to joint inflammation that PRP may complement or substitute for in appropriate cases. Triamcinolone, betamethasone, and methylprednisolone provide potent anti-inflammatory effects through different mechanisms than PRP, and the two approaches address different aspects of joint disease. While corticosteroids rapidly suppress inflammation, PRP supports tissue healing without the potential cartilage and metabolic concerns associated with repeated corticosteroid use. Some practitioners use both approaches in staged fashion depending on disease characteristics and treatment goals.

Hyaluronic acid provides joint lubrication and mild anti-inflammatory effects through mechanisms complementary to PRP's growth factor stimulation. Combining hyaluronic acid with PRP in joint injections addresses both viscosupplementation needs and regenerative support. Polysulfated glycosaminoglycan (Adequan) administered intramuscularly supports joint health through yet another mechanism, often used alongside intra-articular therapies. Systemic joint supplements containing glucosamine, chondroitin, and other compounds provide nutritional support for joint tissues. Your veterinarian can develop comprehensive treatment protocols incorporating appropriate combinations of these therapies based on individual patient needs and the specific condition being addressed.